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The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising,
as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever
screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.Cyclin dependent kinases (CDKs) were
originally discovered through their role in
cell cycle regulation and subsequently
have been shown to act as key regulators
of transcription. All thirteen members of
the human CDK family share the same
architecture and are activated by one of
over ten possible cyclins. X-ray structures
are now available for CDK1, CDK2, CDK4,
CDK7, and CDK9. The strong link
between CDKs and the cell cycle has led
to considerable activity in developing
specific CDK inhibitors as potential
cancer therapeutics that would block
cell proliferation in tumors where cell
cycle control has been lost. However, it
has become evident that there are
a number of built-in parallel or redundant
pathways possibly regulated by different
cyclin/CDK complexes (CDK1 is the only
essential cell cycle kinase) (Barriere
et al., 2007). A major biological challenge
is to tease out the roles of the various cy-
clin/CDKs. For example, two anticancer
compounds now in clinical trials (R-rosco-
votine, selecilib from Cyclacel and flavo-
piridol, and alvocidib from Aventis) were
originally developed as CDK2-specific
cell cycle inhibitors, though it now
appears that CDK9 inhibition and tran-
scriptional repression plays amore impor-
tant role (Fischer and Gianella-Borradori,
2005; Chen et al., 2005). The work pre-
sented by Wang et al. (2010) from the
Cyclacel teammakes an important contri-
bution to this story by developing a set of
chemical tools that show distinctive inhib-
itory profiles against CDKs that control
transcription by regulating the phosphor-
ylation state of RNA polymerase II. This
is an impressively comprehensive piece
of work covering chemistry, protein struc-
ture, cell biology, and in vivo testing.
A cell-based screening cascade was
devised to distinguish ‘‘cell cycle CDKs(1,2,4)’’ inhibitors from ‘‘transcriptional
CDK (7,9)‘‘ inhibitors (i.e., those that act
via RNA polymerase II). By measuring
the relative changes of concentration of
p53 and MI (mitotic index, the ratio
between the number of cells in mitosis
and the total number of cells), three
different classes of inhibitor were identi-
fied: class 1 (transcriptional inhibitors
showing a decrease in MI and high levels
of p53 caused by downregulation of the
p53 regulator Mdm2); class 2 (mitotic
inhibitors); and class 3 (cell cycle inhibi-
tors). A clever analysis correlating antipro-
liferative effects with biochemical CDK
selectivity showed that for class 1
compounds, CDK9 inhibition was neces-
sary and sufficient to kill transformed
cells. The emerging story is that the tran-
scriptional inhibitors that block CDK9
and CDK7 induce apoptosis specifically
in tumor cells by a mechanism that
involves caspases.
These new biochemical results come
on the heels of recently published struc-
tures of the heterodimeric complex of
CDK9 with cyclin T, also known as PTEFb
(positive transcription elongation factor
b). In a twist to the CDK story, the X-ray
structure of a complex of PTEFb with
HIV-1 Tat has been solved, opening up
new possibilities for the development of
new families of anti HIV therapy with
CDK9/CycT as a target (Tahirov et al.,
2010). More relevant to this paper are
the X-ray structures of the complexes
of PTEFb with the small molecule inhibi-
tors flavopiridol (Baumli et al., 2008)
and 5,6-dichlorobenzimidazone-1-b-D-ri-
bofuranoside (DRB), a widely used inhib-
itor of transcription elongation (Baumli
et al., 2010). All PTEFb structures show
a large rotation of the CycT domain
when compared with other cell cycle
CDK/cyclin complexes. Intriguingly, theChemistry & Biology 17, October 29, 2010 ªstructure of DRB crystallized with CDK2
showed surprising differences in the
binding mode of the inhibitor in the ATP
active site when compared with CDK9.
These differences were attributed to an
inherent flexibility of CDK9 in complex
with CycT compared with the more rigid
conformation of CDK2 in complex with
CycA.
Even with the availability of such
detailed structural information on different
CDKs, it is still difficult to design or predict
isoform-specific inhibitors because of the
highly conserved ATP binding site. The
structure activity relationship (SAR) devel-
oped by Wang et al. (2010) suggests that
the few amino acid differences along the
sequence linking the CDK N-terminal
domain and C-terminal domain may play
an important role: forCDK2, this sequence
is 81EFLHQDLKK89 and is highlighted in
Figure 1. Importantly, the fourteen or so
2-anilinopyrimidine inhibitors described
in thepaper showawide rangeof specific-
ities and activities. An X-ray structure of
the most potent CDK9-specific inhibitor
(compound 14) complexed with CDK2
shows that the weaker interaction
with CDK2 is likely caused by an unfavor-
able electrostatic and steric interaction
between the piperazine group and
Lys89. The equivalent residue to this
lysine is valine in CDK7 and glycine in
CDK9 (Figure 1), providing more space
for the large piperazine substituent. Inter-
estingly, Lys 89 in the CDK2 structure is
situated on the first turn of a short helix;
changing this to glycine in CDK9 will also
have an effect on the flexibility of this inter-
domain hinge region—a result that is also
in keeping with the structural data from
Baumli et al. Thus inhibitor specificity for
a particular CDK isoform is likely to be
governed by flexibility as well as shape
and charge complementarity.2010 Elsevier Ltd All rights reserved 1047
Figure 1. General Overview of CDK Nucleotide Binding Site with Inhibitor 14 Bound
Conserved interactionswith all CDKs are shown as dotted blue lines. Differences along the linking sequence between the N- andC-terminal domains (depicted as
thick black lines in the scheme and the protein structure) are thought to play an important role in inhibitor specificity. This sequence is EFLHQDLKK in CDK2,
DFMETDLEV in CDK7, and DFCEHDLAD in CDK9. The final residue in these sequences seems crucial for the specificity of inhibitor 14. The piperazine moiety
(highlighted in green) occupies space allowed by small side chains (e.g., Gly in CDK9), resulting in a lowKi; however it interacts unfavorably with larger side chains
(e.g., Lys in CDK2), resulting in a lower affinity. Hence, it is selective between the CDKs.
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in vivo testing and it shows good
antitumor activity with an IC50 value of
0.3 mM and up to 40-fold selectivity
toward a range of transformed cell lines.
This compound also shows an impressive
activity in solid tumor xenograft models
producing a 10 day delay in tumor growth
(compared to one day for the control 5
flurouracil treatment). The results pro-
vided in this paper provide an encour-
aging advance on the development of
specific transcriptional-type CDK inhibi-
tors and suggests that downregulation of
RNA-polII activity in transformed cells1048 Chemistry & Biology 17, October 29, 20will provide a useful therapeutic approach
against cancer. The next big step will be
to test clinically whether these antitran-
scriptional inhibitors are more efficacious
and less toxic than CDK inhibitors with
a broader specificity.
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